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Abstract
Background: Chemotherapy-related fatigue (CRF) is a common symptom in non-small cell lung cancer (NSCLC)
patients. A Chinese herbal formula cream for oral application, called Jianpishengsui (JPSS), is extensively used in the
First Affiliated Hospital of Guangzhou University of Chinese Medicine as an internal preparation for CRF and is
associated with a promising response. Due to the lack of high-quality clinical evidence, a randomized placebo-
controlled trial is required to assess the efficacy and safety of JPSS.
Methods/design: The efficacy and safety of JPSS herbal formula cream will be evaluated through a prospective,
randomized, placebo-controlled trial conducted in the First Affiliated Hospital of Guangzhou University of Chinese
Medicine. NSCLC patients with CRF will be randomized into two groups at a ratio of 1:1. Each group will receive
either 15 g of the oral JPSS herbal formula cream or placebo twice a day from day 6 to day 20 during two courses
of paclitaxel + platinum/docetaxel + platinum/pemetrexed + platinum (TP/DP/AP) chemotherapy. The primary
endpoint is the difference in the degree of fatigue between baseline (the day before the start of the intervention)
and day 42, which will be assessed by the Revised Piper Fatigue Scale score. The secondary endpoints are quality of
life (measured by the 43-item European Organization for Research and Treatment of Cancer Quality of Life
Questionnaire—Lung Cancer C43), Eastern Cooperative Oncology Group Performance Status, and Traditional
Chinese Medicine syndrome score. The toxicity of the treatments will also be evaluated at the same time. All
outcomes will be measured at baseline, day 6, day 21, and day 42 of the treatment.
Discussion: This randomized trial will investigate the efficacy and safety of JPSS applied for CRF in patients with
NSCLC.
Trial registration: Chinese Clinical Trial Registry, ChiCTR1900023451. Registered on 28 May 2019.
Keywords: Chemotherapy-related fatigue, Cancer-related fatigue, Non-small cell lung cancer, Jianpishengsui, Herbal
formula cream
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Introduction
Lung cancer is a major factor contributing to cancer-
related death worldwide. It is estimated that non-small
cell lung cancer (NSCLC) accounts for approximately
85% of lung cancer incidence [1]. Most NSCLC patients
are diagnosed at an advanced stage, which leads to a
very large reliance upon systemic chemotherapy. It is es-
timated that 80–96% of patients suffer from
chemotherapy-related fatigue (CRF) [2, 3]. CRF has a
profound negative impact on the patients’ quality of life.
Patients usually have symptoms such as loss of appetite,
dry mouth, anxiety, tension, nausea, and insomnia.
These symptoms may last for a long period and cannot
be alleviated by rest or sleep, leading to treatment inter-
ruption or delay amongst patients. CRF belongs to the
category of cancer-related fatigue, which is mainly expe-
rienced by patients undergoing chemotherapy [4].
In recent years, scholars have noted that the potential
pathogenesis of CRF may be related to anaemia [5], abnor-
mal regulation of cytokines [6, 7], abnormal regulation of
hypothalamic–pituitary–adrenal axis function, [8] dysrhyth-
mia, [9] and skeletal muscle atrophy [10]. Chemotherapy-
induced anaemia is considered one of the leading causes of
CRF [11]. However, not all patients who experience exhaus-
tion have anaemia, and most patients continue to feel
weariness after recovery. At present, no standard therapies
are available for treating CRF. Physical exercise, such as Tai
Chi, yoga, family sports, nursing guidance, physical therapy,
and psychosocial intervention, has been widely recognized
as an effective method to overcome CRF [12, 13]. However,
patients with CRF, especially those with a severe index, are
usually too weak to perform traditional exercise. While the
underlying mechanism of CRF remains unclear, there is
currently no recognized safe and low-toxic specific drug for
its treatment [14]. Previous studies have focused mostly on
the use of haematopoietic growth factors, psychostimulants,
dexamethasone, or antidepressants to treat CRF, but the re-
sults have been mixed [15–18]. Alternatively, traditional
Chinese medicines, such as acupuncture [19] and herbal
extract formula creams, have become a treatment option
for Chinese patients. The herbal extract formula cream is
widely used for the prevention and treatment of chronic
diseases in China [20–22].
According to the theory of Chinese medicine, both Qi
and blood are basic and vital components of the human
body and can maintain activities of living. Qi [23] refers
to the energy flow of the body (or a vitality of the body),
which maintains blood circulation, warms the body, and
fights against disease. In Traditional Chinese Medicine
(TCM), blood deficiency [24] is considered a patho-
logical state of blood dysfunction and organ dystrophy,
which is often caused by spleen and stomach deficiency,
haematopoiesis, and blood stasis. Qi and blood supple-
ment each other and support vigour. Qi and blood
deficiency are the main pathogenic factors involved in
CRF [25]. Qi and blood deficiency syndrome are com-
monly accompanied by fatigue, shortness of breath, de-
creased activity, poor sleep, and loss of appetite.
Based on the clinical experience of Professor Lizhu
Lin, a well-known TCM oncologist, we developed an in-
ternal preparation called Jianpishengsui (JPSS) herbal
formula cream in the First Affiliated Hospital of
Guangzhou University of Chinese Medicine. JPSS has
been the most commonly used formula to treat CRF for
the past 4 years (hospital preparation approval number
Z20151106). A previous study showed that JPSS has a
good effect on patients with CRF, and no adverse reac-
tions have been reported. Yu Ling [26] conducted a pro-
spective, randomized, controlled study to assess the
effectiveness of JPSS on cancer-associated anaemia. One
hundred and eleven patients were randomly divided into
the experimental group (51 cases) or the control group
(60 cases). The experimental group was treated with
JPSS combined with erythropoietin for a total of 42 days,
while the control group was treated with erythropoietin
alone. The results showed that the RBC and Hb levels
were significantly improved in the experimental group,
while the Piper scores were significantly reduced (p <
0.05), which indicated that JPSS might have a remark-
able influence on CRF [26]. JPSS is a mixed Chinese
herbal formula cream consisting of 17 different herbs, of
which Codonopsis pilosula and Carapax Trionycis are
the main components. Each of these herbs can synergis-
tically nourish Qi and blood, and relieve fatigue to a cer-
tain extent. Syndrome differentiation is the core concept
of TCM. For this reason, we chose patients with both Qi
and blood deficiency as the target population.
In comparison with the traditional decoction, the
herbal formula cream is easy to use because it can be
stored in the refrigerator and taken with water. Previous
studies have found that JPSS has a good effect on fatigue
caused by cancer-related anaemia with few side effects.
We are also applying for a patent for the JPSS herbal
formula cream. Despite its extensive clinical use, the
safety and efficacy of JPSS for treating CRF have not
been investigated in a prospective, randomized clinical
study. Therefore, there is a need to conduct a JPSS inter-
vention study for NSCLC patients with moderate-to-
severe fatigue.
Methods/design
Design and setting
A prospective, randomized, placebo-controlled trial, as
shown in Fig. 1, will be performed on NSCLC patients
in a single centre during the advanced stage of CRF.
Fifty patients with deficiency of Qi and blood syndrome
and CRF will be selected and then randomly divided into
two equal-sized groups: the JPSS group and the P group.
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The JPSS group will receive treatment with the JPSS
herbal formula cream, while the P group will receive the
placebo formula cream. Both groups will receive the
JPSS herbal formula cream or the placebo from day 6 to
day 20 during the two courses of paclitaxel + platinum/
docetaxel + platinum/pemetrexed + platinum (TP/DP/
AP) chemotherapy.
This trial has been approved by the Ethics Committee
of the First Affiliated Hospital of Chinese Medicine (No.
ZYYECK[2018]045).
Participants
The project will be carried out in the First Affiliated
Hospital of Guangzhou University of Chinese Medicine
by recruiting patients from either outpatient or inpatient
settings.
Participants will be recruited through advertisements
and referrals from 1 July 2019 to 31 November 2019.
Advertisements will include social media, posters, and
flyers in hospital and public areas, such as the cancer
centre and outpatient waiting halls.
Patients with a diagnosis of NSCLC (TNM stages
IIIb–IV) based on pathology or cytology, a diagnosis of
moderate-to-severe fatigue, and a diagnosis of Qi and
blood deficiency syndrome can be enrolled in this study.
The diagnostic criteria and TNM classification for
NSCLC are based on the Guidelines for Diagnosis and
Treatment of Common Cancers in China (Chapter of
Malignant Neoplasm). The diagnostic criteria for CRF
are based on the 10th revision of the International Clas-
sification of Diseases. Patient-reported fatigue severity is
measured using the Revised Piper Fatigue Scale (RPFS).
The diagnosis of Qi and blood deficiency syndrome cri-
teria is based on the Guidance Principle of Clinical Re-
search on New Drug of Traditional Chinese Medicine
(2002 edition) [27].
Qi deficiency syndrome can be diagnosed on the
basis of two main symptoms and one secondary
symptom as follows: main symptoms include short-
ness of breath, lack of strength, fatigued spirit, and
vacuous pulse; secondary symptoms include spontan-
eous sweating, short speech, and pale tongue. Blood
deficiency syndrome can be diagnosed on the basis of
two main symptoms and one secondary symptom as
follows: main symptoms include pale white or sallow
complexion, dizziness, clouded flowery vision, and
palpitations; secondary symptoms include insomnia,
numbness of extremities, and abnormal menstruation
(e.g., deferred, scanty, or light colour of menstru-
ation). Any patients who meet both of these criteria
will be diagnosed with Qi and blood deficiency
syndromes.
Fig. 1 Flow chart of the trial procedure. ECOG-PS Eastern Cooperative Oncology Group performance status, EORTC QLQ-LC43 43-item European
Organization for Research and Treatment of Cancer Quality of Life Questionnaire C43, JPSS Jianpishengsui, RPFS Revised Piper Fatigue Scale, TCM
Traditional Chinese Medicine
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Recruitment procedure
The potential participants will be contacted in outpatient
or inpatient settings before enrolment. Patients who
have received at least one course of treatment and no
more than four courses of chemotherapy will be re-
cruited as potential subjects. A TCM oncologist trained
in TCM diagnosis and modern oncology will screen the
medical eligibility of the patient. Written informed con-
sent from all participants is required before enrolment,
and patients will have sufficient time to decide whether
to participate before signing the consent form. After an
assessment of CRF severity and other relevant entry cri-
teria within a week before the start of the intervention,
enrolment will be confirmed, and baseline characteristics
including sex, age, body mass index, pathological type,
baseline RPFS, ECOG score, and disease history will be
recorded. Participants will undergo blood tests, including
full blood count, urine analysis, stool analysis, liver func-
tion test, and renal function test, at baseline, day 6, day
21, and day 42.
Inclusion criteria
1. NSCLC diagnosis (TNM stages IIIb–IV) based on
pathology or cytology
2. Moderate-to-severe fatigue (with RPFS score ≥ 4)
after cancer diagnosis due to cancer therapy or
cancer itself
3. Wild type or unknown driver gene
4. TCM syndrome differentiation in line with the
diagnostic criteria of Qi and blood deficiency
syndrome
5. Experience with at least one and a maximum of
four cycles of chemotherapy and plan to receive
chemotherapy (TP/DP/AP scheme) for at least two
courses
6. Age range: 18–75 years
7. ECOG score ≤ 2
8. Voluntary participation with written informed
consent
9. No use of antidepressants or other psychotropic
drugs within 1 month of enrolment in the study
10. Willingness to participate in surveys and ability to
complete the questionnaires independently with
clear consciousness and without cognitive or
psychotic disorders
Exclusion criteria
1. Treatment with EGFR/ALK-targeted medicine or
PD-1/PD-L1 immune checkpoint blockade therapy
2. Allergy to JPSS granules (including patients who
have allergies to any component of the
prescription); allergy to black beans or bean
products
3. Patients with uncontrollable infections that require
the use of anti-inflammatory drugs
4. Anaemia, defined as haemoglobin level < 90 g/L or
PLT < 50 × 109/L within 2 weeks from the date of
enrolment
5. Thyroid disorder with abnormal thyroid-stimulating
hormone and free T4 levels
6. Any significant comorbidity, such as severe
insomnia or depression and reduced oral intake
7. Pregnancy or lactation
8. Severe liver or kidney dysfunction (serum
creatinine ≥ 1.5 times ULN; ALT or AST ≥ 1.5 times
ULN; bilirubin ≥ 1.5 times ULN) or a history of
hepatitis A, B, or C
9. Current use of the following drugs: ginseng,
methylphenidate, modafinil, phenobarbital,
phenytoin, clonidine, or tricyclic antidepressants
Interventions
The treatment group will receive 15 g of the JPSS herbal
formula cream twice daily from day 6 to day 20 for each
course of chemotherapy, for 30 days in total. The control
group will receive 15 g of the placebo formula cream
twice daily for 30 days in total; the main ingredients of
the placebo are broken-down black soya bean, Guiling
jelly, caramel colour, and Yuan Zhen sugar. The fabrica-
tion method, appearance, smell, and taste are similar to
those of JPSS. The JPSS herbal formula cream and the
matching placebo used in this trial are manufactured by
the First Affiliated Hospital of Guangzhou University of
Chinese Medicine in a way that meets the requirement
of the Good Manufacturing Practice (GMP).
Patients will take the cream orally on their own and
receive instructions. Customized spoons and measuring
cups will be provided. The using method of JPSS: direc-
tions—put 15 g of JPSS into a cup, stir it with warm
water, and take it twice a day after breakfast and dinner;
storage—away from light below 20 °C is recommended;
and any discomfort while taking the medication should
be reported to the researcher using the published tele-
phone number.
All patients will receive JPSS or placebo during two
courses of platinum-based chemotherapy. The specific
scheme and dosage were established according to the
US National Comprehensive Cancer Network (NCCN)
clinical practice guidelines in oncology. The recom-
mended platinum-based chemotherapies are the TP/DP/
AP scheme. A research nurse will observe every patient
once a week. Follow-up information on adverse effects,
compliance, and combined use of other medicines will
be collected through interviews, telephone calls, and
questionnaires.
Xiao et al. Trials           (2020) 21:94 Page 4 of 9
The Jianpishengsui (JPSS) herbal formula cream is one
of the most commonly used hospital internal prepara-
tions. The recipe is an empirical prescription from Pro-
fessor Lizhu Lin. The herbal formula cream is made of
multiple Chinese medicines, and the main ingredients
include the following:
 Carapax Trionycis
 Cervus nippon Temminck
 Codonopsis pilosula
 Lycium chinense Miller
 Polygonatum sibiricum
 Fructus Ligustri Lucidi
 Herba Ecliptae Eclipta prostrala L
 Pericarpium Citri Reticulatae
 Endothelium Corneum Gigeriae Galli
Preparation of the JPSS is as follows: soaking (add the
ingredients to a specific decocting bag, add cold water in
an amount 10 times that of the herb, and continuously
soak the ingredients in the decocting machine for 12 h);
decoction (first, perform the first decoction for 2 h and
then filter the solution; second, add six times the
amount of water to the herbs for 1 h for the second de-
coction, and then filter the solution; and third, mix the
two solutions); concentration (pour the mixed solution
into a high-pressure vacuum concentration decocting
machine to concentrate it under constant temperature
(~60–70 °C) until it turns into a light cream); and col-
lecting the cream (transfer the light cream to a thermo-
static capacitor to continue to concentrate it until there
is no vapour; then, collect and package the herbal for-
mula cream). A box of JPSS weighs 500 g and is recom-
mended to be stored away from light at a temperature
below 20 °C.
Randomization
We will use the minimum randomization method to
perform randomization. Eligible patients will be random-
ized into the JPSS group and the placebo (P) group in a
1:1 ratio for a target total of 50 patients. Patients will be
randomized by the Statistical Analysis System (SAS 9.4
software). The process will be performed by an inde-
pendent statistician in the Clinical Research Center,
South China Research Center for Acupuncture and
Moxibustion, Guangzhou University of Chinese
Medicine.
Blinding
Only the independent statistician will know the group
situation and have access to the randomization list and
blinding codes. The independent statistician will label
the cream according to the blinding codes and then tear
off the marking label that distinguishes the placebo from
the JPSS cream. He will not be involved in the outcome
data analysis. The research pharmacy is responsible for
the distribution of the cream. This study will be a
double-blind trial in which both the participants and re-
searchers, including nurses, physicians, and analysing
statisticians, are blinded to the allocated treatment.
The randomization schedule will be hidden until all
interventions are assigned and registration, follow-up,
data collection, data cleansing, and analysis are com-
pleted. Blinding will be ensured using a placebo of the
same colour, size, shape, and taste. The quality of the
test product, such as the content, solubility, and bacterial
contamination, will be strictly controlled by GMP stan-
dards and tested and verified by the researchers.
Outcome measurements
The primary outcome is the difference in the Revised
Piper Fatigue Scale (RPFS) score compared in the two
groups between baseline (the day before the start of the
intervention) and day 42. Secondary outcome measures
include quality of life (QoL), Eastern Cooperative Oncol-
ogy Group Performance Status (ECOG-PS), and TCM
syndrome scores. Patients’ demographic data, including
age, sex, body mass index, histopathological type, and
past medical history, will be recorded at the time of
entry into the study. The patients’ safety will be moni-
tored throughout this study.
Revised Piper Fatigue Scale
The Revised Piper Fatigue Scale (RPFS) is a self-rating
scale and a multidimensional assessment tool that has
been widely used to measure CRF [28]. Four dimensions
are encompassed in the RPFS, including behavioural/se-
verity (six items), affective meaning (five items), sensory
(five items), and cognitive/mood (six items). There are a
total of 22 items in the RPFS. Every item is scored on a
scale of 0–10, with 0 representing no fatigue, 1–3 repre-
senting light levels of fatigue, 4–6 representing mild
levels of fatigue, and 7–10 representing high levels of fa-
tigue. The more severe the fatigue, the higher the score
will be. Researchers will assess the RPFS score at base-
line, day 6, day 21, and day 42.
EORTC QLQ-LC43
The European Organization for Research and Treatment
of Cancer Quality of Life Questionnaire—Lung Cancer
43 (EORTC QLQ-LC43) is an instrument for assessing
QoL in lung cancer patients. The EORTC QLQ-LC43
contains the EORTC QLQ-C30 and the EORTC QLQ-
LC13 [29]. The former involves five functional domains
(physical, cognitive, emotional, role, and social), three
symptomatic domains, one overall quality-of-life do-
main, and six single domains. The latter involves 13 spe-
cific items for lung cancer. Their reliability, validity, and
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responsiveness have been verified in China [30]. The de-
tailed scoring method will refer to the literature. The
evaluation will be performed at baseline, day 6, day 21,
and day 42.
ECOG-PS
The Eastern Cooperative Oncology Group Performance
Status (ECOG-PS) is widely used in clinical practice to
assess a patient’s general condition. The evaluation will
be performed at baseline, day 6, day 21, and day 42.
TCM syndrome scores
TCM syndrome scores will be assessed according to the
Guidance Principle of Clinical Research on New Drug of
Traditional Chinese Medicine (2002 edition) [27], which
is widely used in the evaluation of TCM syndrome in
China. The efficacy is classified into clinical recovery,
markedly effective, effective, and non-effective: clinical
recovery, TCM clinical symptoms disappeared or symp-
tom score reduction ≥ 95%; markedly effective, symptom
score reduction ≥ 70% and < 95%; effective, symptom
score reduction ≥ 30% and < 70%; and non-effective, no
significant improvement in clinical symptoms of TCM
or symptom score reduction < 30%. The calculation for-
mula is based on the nimodipine method: Efficacy
index = [(score before treatment – score after treatment)
/ score before treatment] × 100%. The evaluation will be
performed at baseline, day 6, day 21, and day 42.
Safety assessments
The routine blood panel, urine analysis, liver function
test, renal function test, haemagglutination test, and
ECGs will be investigated before and after completing all
the interventions. Adverse events (AEs) during treatment
will be classified according to the US National Cancer
Institute, Common Terminology Criteria for Adverse
Events v4.0 (NCI CTC 4.0). Once grade 3–4 AEs occur,
we will address AEs in a timely manner. All AEs will be
observed and documented in detail. All abnormal
changes from the baseline laboratory tests will be
evaluated.
Sample size calculation
The Revised Piper Fatigue Scale (using a 0–10 scoring
system: higher scores indicate higher severity) score is
deemed the primary therapeutic index. The sample size
calculation was based on our pilot study, which included
22 patients in the analysis and showed that the RPFS
score in the JPSS group was 53.21 ± 23.10 and the RPFS
score in the P group was 91.13 ± 44.36 after two courses
of treatment. Power Analysis and Sample Size (PASS,
version 15, NCSS, 201) software was used to perform
the sample size calculation. A sample size of 25 patients
in each group was required to detect a significant
difference (p < 0.05) between the two groups, with a bi-
lateral 5% type I error and a power of 90%, assuming a
20% dropout rate. In summary, a total of at least 50 pa-
tients are required. The sample size calculation was per-
formed by the Clinical Research Center, South China
Research Center for Acupuncture and Moxibustion,
Guangzhou University of Chinese Medicine.
Data management and quality control
Three research nurses involved in this study have been
trained and have obtained corresponding knowledge.
One nurse will call each patient every week to monitor
compliance with the cream. Moreover, the other two
nurses will help with the assessment of the mentioned
questionnaires. Whenever there are unusual situations,
including possible AEs, the nurses are required to report
them to the researcher in a timely manner and record it.
A brief diagram of the study schedule is shown in Fig. 2.
Statistical analysis
The data will be analysed according to the intention-to-
treat (ITT) principle. The primary objective is to deter-
mine whether the average improvement in CRF from
baseline to day 42 in patients receiving JPSS is different
from that in patients receiving the placebo. A repeated-
measures analysis of variance (ANOVA) will be used to
examine the effect of the interventions and time on the
RPFS. If the data are normally distributed, the t test will
be used to analyse the scores for the RPFS, EORTC
QLQ-LC43, and TCM syndrome between the experi-
mental group and the placebo group. Stratified analysis
according to different chemotherapy schemes and the
number of cycles will be used to analyse the differences
in the RPFS, EORTC QLQ-LC43, and TCM syndrome
scores. The baseline characteristics of patients, including
sex, age, body mass index, and histopathological type,
between the experimental group and the control group
will be compared using the chi-squared test. The num-
ber of patients experiencing adverse events (AEs) will be
compared between these two groups using the chi-
squared test. p < 0.05 (two-sided) will be considered sta-
tistically significant. All analyses will be performed using
SPSS version 22.0.
We will check and analyse the reasons for missing
data. The missing values will be estimated using the last
observation method (LOCF) [31]. After the main ana-
lysis is completed, sensitivity analysis will be performed
on each dataset to evaluate the impact of missing data
on the test results.
Ethics statement
This study has been approved by the Ethics Commit-
tee of the First Affiliated Hospital of Guangzhou
University of Chinese Medicine (approval number:
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No. ZYYECK[2018]045). All participants will be in-
formed of the details of the study and sign informed
consent.
Discussion
CRF may occur at any time, and it may last for a long
period even after cancer goes into remission. Given the
high morbidity of fatigue in cancer patients, researchers
have put a great deal of effort into the study of the
mechanism and treatment of CRF. Despite this effort,
there is still no substantial clinical evidence in support
of the currently available drugs [32]. Currently, an
increasing number of CRF patients choose to use herbal-
related products to improve their health conditions, and
TCM may become a popular alternative for CRF patients
with a broad application perspective [33]. The JPSS
herbal formula cream, which is used extensively in our
hospital as an internal preparation for CRF, is considered
an essential complementary therapy with beneficial ef-
fects. Early clinical application and observation have
also laid a foundation for its use. Due to the lack of
quality randomized placebo-controlled trials at
present, we designed this study to evaluate the effi-
cacy and safety of JPSS.
Fig. 2 Study schedule
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Some studies have shown that TCM herbal products are
effective and safe for the treatment of CRF. A prospective
trial was conducted to assess Ren Shen Yang Rong Tang
(RSYRT) decoction for CRF; fatigue severity decreased sig-
nificantly before therapy to 6 weeks after therapy, from 7.06
to 3.30 on a 0–10 scale, and no discomfort or toxicity was
observed [34]. In another randomized control trial, 40 pa-
tients with cancer-related fatigue were randomized into
two groups: an oral Bojungikki-tang group or a waitlist
group. After 2 weeks, the Bojungikki-tang group showed
statistically significant improvements in fatigue level,
assessed by the Visual Analogue Scale of Global Fatigue
(VAS-F) measuring the severity of fatigue (experimental vs.
control: − 1.1 ± 2.1 vs. 0.1 ± 0.9, p < 0.05). The results indi-
cated that Bojungikki-tang offers strong evidence in terms
of CRF and QoL in cancer patients [35]. Similarly, Lv WJ
[36] demonstrated that Yiqi Chutan decoction had an ad-
vantage for treating CRF. A total of 83 NSCLC patients
were randomized into a treatment group (41 cases) and a
control group (42 cases). The treatment group was given
Yiqi Chutan Decoction combined with DP/GP, while the
control group received DP/GP only. After two treatment
cycles, the CRF severity in the treatment group was signifi-
cantly alleviated compared with that in the control group,
with fewer adverse reactions observed [36].
Several preliminary clinical studies have also been con-
ducted to assess the effectiveness of the JPSS formula
cream for patients with CRF. A prospective, randomized,
controlled study was conducted as already mentioned,
which indicated that JPSS might have a remarkable in-
fluence on CRF.
We aim to conduct this trial to evaluate the efficacy and
safety of JPSS for treating CRF in NSCLC patients and
provide high-quality clinical evidence in this area. How-
ever, there are some limitations to our study. First, fatigue
may persist for a long time after the end of treatment.
However, the intervention and follow-up will only last for
two courses of chemotherapy, which cannot indicate and
assess the long-term efficacy of JPSS during the whole
four to six cycles of chemotherapy. A longer intervention
and observation period will be our future research direc-
tion. Second, to expand the target group, the chemother-
apy regimen and the number of cycles will not be required
to be the same in this research. Therefore, we will conduct
a stratified analysis according to different schemes and the
number of cycles. Based on its herbal ingredients and its
convenience of use, we consider the herbal formula cream
a promising herbal formula that is worthy of being studied
and used for chronic diseases, especially for CRF that re-
sults in persistent fatigue.
Trial status
This trial have begun to recruit participants in August
2019 using protocol version 3.0, dated 24 September
2018, and recruitment is expected to be completed in
February 2020.
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